MyoMed 205
Product Specifications
UNSPSC Description
MyoMed-205 is an inhibitor targeting the activity of MuRF1. MyoMed-205 prevents early diaphragmatic systolic dysfunction and atrophy due to unilateral diaphragmatic nerve denervation 12 hours later. MyoMed-205 reduces ubiquitination and subsequent proteasomal degradation of muscle proteins by inhibiting MuRF1 activity. MyoMed-205 increases levels of a protein that phosphorylates Akt (ser473), an important signaling molecule for muscle growth and maintenance. MyoMed-205 can be used to study and treat diaphragmatic dysfunction and atrophy (DIDD) caused by early apraxia, especially in clinical situations such as diaphragmatic paralysis or mechanical ventilation[1].
Target Antigen
Proteasome
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Field of Research
Others
Assay Protocol
https://www.medchemexpress.com/myomed-205.html
Solubility
DMSO : 25 mg/mL (ultrasonic;warming;heat to 60°C)
Smiles
O=C1OC2=C(C(C)=C1)C=CC(OCC3=CC=C(C(NCCNC(NCC4=CC=CS4)=O)=O)C=C3)=C2
Molecular Weight
491.56
References & Citations
[1]Ribeiro F, et al. Small-Molecule Inhibition of MuRF1 Prevents Early Disuse-Induced Diaphragmatic Dysfunction and Atrophy[J]. International Journal of Molecular Sciences, 2023, 24(4): 3637.
Shipping Conditions
Blue Ice
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-164027/MyoMed-205-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-164027/MyoMed-205-SDS-MedChemExpress.pdf
Clinical Information
No Development Reported
CAS Number
2614161-13-4
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS1454748-01 0.02 mg (E-Coli)
Recombinant Neisseria meningitidis serogroup B Phosphoribosylaminoimidazole-succinocarboxamide synthase (purC)
Ask
View Details 
MBS1454748-02 0.02 mg (Yeast)
Recombinant Neisseria meningitidis serogroup B Phosphoribosylaminoimidazole-succinocarboxamide synthase (purC)
Ask
View Details